ScreenerHero

ACBAurora Cannabis Inc.

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · auroramj.com
3.940USDMkt Cap: 249.44M $P/E: —

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and m…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap249.44M $
Enterprise Value178.21M $
Revenue (TTM)314.07M $
Gross Profit136.65M $
Net Income (TTM)-135.96M $
Revenue/Share5.408 USD
Last Price3.940 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees1.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA05156X8843
Valuation
P/E (Trailing)—
P/E (Forward)-35.82
PEG—
EV/EBITDA-5.95
EV/Revenue0.57
P/S0.79
P/B0.65
EPS (TTM)-0.67
EPS (Forward)-0.11
52W Range
3.81087% of range3.960
52W High3.960 USD
52W Low3.810 USD
Profitability
Gross Margin42.62%
Oper. Margin-12.92%
EBITDA Margin-9.54%
Profit Margin-42.41%
ROE-26.56%
ROA-22.62%
Growth
Revenue Growth-8.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.51M $
CapEx (TTM)22.55M $
FCF Margin-6.38%
FCF Yield-8.03%
Net Debt-77.34M $
Net Debt/EBITDA2.58
Balance Sheet
Debt/Equity0.05
Current Ratio5.36
Quick Ratio1.92
Book Value/Sh6.041 USD
Cash/Share1.542 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 11, 2020
Splits
Last Split1:10
Split DateFeb 20, 2024
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.63.31M
Float64.46M
Insiders1.21%
Institutions9.34%
Short Interest
Short Ratio6.6d
Short % Out.12.77%
Shares Short8.00M
Short (prev mo.)7.61M
Technical
SMA 502.965 (+32.9%)
SMA 2003.660 (+7.6%)
Beta1.34
S&P 52W Chg19.18%
Avg Vol (30d)1.35M
Avg Vol (10d)2.45M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—